⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12669587 | 1.00 | — | — | |
| SCHEMBL16690584 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL29766621 | 0.98 | DPP4 (0.46) | — | |
| Sulfuric Acid SCHEMBL2306580 | 0.92 | DPP4 (0.42) | — | |
| SCHEMBL12669685 | 0.86 | CA12 (0.52) | — | |
| SCHEMBL4598450 | 0.86 | CA12 (0.52) | — | |
| SCHEMBL12668009 | 0.86 | CA12 (0.52) | — | |
| SCHEMBL4599189 | 0.85 | DPP4 (0.38) | — | |
| SCHEMBL15808463 | 0.82 | DPP4 (0.45) | — | |
| SCHEMBL8626305 | 0.82 | DPP4 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4619106-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | Neupharma, Inc (US) | 2025-09-24 | — | — | EP | claimed |
| EP-4188924-B1 | ANTAGONIST COMPOUNDS | ADORX THERAPEUTICS LTD (GB) | 2025-06-18 | — | — | EP | claimed |
| EP-4071145-B1 | JAK INHIBITOR COMPOUND AND USE THEREOF | LU LIANG (CN) | 2025-01-08 | — | — | EP | claimed |
| WO-2024107753-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | NEUPHARMA, INC (US) | 2024-05-23 | — | — | WO | claimed |
| EP-0964865-B1 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | UPJOHN CO (US) | 2003-03-05 | — | — | EP | claimed |
| EP-0964865-A2 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-22 | — | — | EP | claimed |
| US-5932728-A | ANTIHISTAMINES; ANTIALLERGENS | PHARMACIA & UPJOHN COMPANY (US) | 1999-08-03 | — | — | US | claimed |
| WO-1998042708-A2 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1998-10-01 | — | — | WO | claimed |
| US-20250381202-A1 | PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY | ZOUNEK ALEX (DE) | 2025-12-18 | — | — | US | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| EP-4619106-A2 | TREATMENT OF ASCT2-DEPENDENT CANCERS | Neupharma, Inc (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-4294810-B1 | PROCESS FOR PREPARING HIGH PURITY DEGREE LAROTRECTINIB | OLON SPA (IT) | 2024-10-16 | — | — | EP | disclosed |
| CN-118201928-A | 6-Heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | 艾捷斯治疗公司 | 2024-06-14 | — | — | CN | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| US-20050101616-A1 | Quinazoline analogs as receptor tyrosine kinase inhibitors | ARRAY BIOPHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| US-20030149082-A1 | INHIBITORS OF THE ANANDAMIDE TRANSPORTER AS ANALGESIC AGENTS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2003-08-07 | — | — | US | disclosed |
| EP-0964865-B1 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | UPJOHN CO (US) | 2003-03-05 | — | — | EP | disclosed |
| WO-2002028829-A2 | PEPTIDE DEFORMYLASE INHIBITORS | QUESTCOR PHARMACEUTICALS, INC. (US) | 2002-04-11 | — | — | WO | disclosed |
| EP-0964865-A2 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1999-12-22 | — | — | EP | disclosed |
| WO-1998042708-A2 | PHARMACEUTICALLY ACTIVE TRICYCLIC AMINES | PHARMACIA & UPJOHN COMPANY (US) | 1998-10-01 | — | — | WO | disclosed |